Address: 171 Bath Road, Slough, Berkshire, SL1 4AA, United Kingdom.,United Kingdom
Tel: +44 (0)1753 512000
Established in the UK in 1982, Chiltern has grown steadily and strategically for more than 25 years, building our expertise, systems and client relationships to become one of the world’s leading and most highly trusted Contract Research Organizations.
From the start, our emphasis has been on delivering innovative and efficient solutions for our clients. This has developed a culture where customer focus, collaboration, flexibility and quality drive all aspects of our business.
Today, Chiltern employs nearly 1,300 staff globally and has experience conducting clinical trials in more than 40 countries. We are located strategically in the Asia Pacific region, Europe, Latin America, North America and South Africa to align with and respond to our clients’ evolving needs.
Our senior management team is truly international, reflecting Chiltern’s global commitment to providing the best clinical development services to our clients worldwide. Through their leadership, experience and active involvement, Chiltern offers our clients global coverage and ready access to Chiltern’s leadership at all levels, which drives innovation, facilitates issue escalation and resolution and creates a highly efficient and responsive environment, translating into cost and time savings and delivery success.
Chiltern provides full clinical research services from Early Phase to Late Phase:
Early Phase
Global Clinical Development
Late Phase
Biometrics
Medical and Regulatory Affairs
Resourcing Solutions
Given the global trend of clinical research increasingly being outsourced to emerging markets, such as Asia and Latin America, where does this leave historical hubs of clinical research such as…
Mark Hicken, managing director of the UK and Ireland operations of Janssen, the pharmaceutical arm of Johnson & Johnson, highlights the company’s long-standing R&D presence in the UK. He calls…
Sir Robert Lechler, president of the Academy of Medical Sciences (AMS), discusses the Academy’s role in promoting medical research in the UK and how that stands to change in the…
Keith Thompson, CEO of the Cell & Gene Therapy Catapult, one of a number of Catapult institutions in the UK designed to help commercialize innovative research, discusses strategy, funding, international…
Terry O’Regan, VP and managing director at Biogen UK and Ireland, discusses the company’s longstanding commitment to the UK, market access issues, and why Biogen is staying the course with…
Sir John Savill, chief executive of the Medical Research Council between 2010 and 2018, discusses the organization’s transition into part of the new UK Research and Innovation (UKRI) grouping, the…
Steve Ford, CEO of Parkinson’s UK, one of the UK’s leading research-based charities, discusses his organization’s recent Digital Leadership Award, presenting the needs of Parkinson’s patients to stakeholders, and why…
Tony Jones, CEO of One Nucleus, a life sciences membership organization centered on the Greater London-Cambridge-East of England corridor, discusses the role of SMEs within the UK’s healthcare ecosystem, translational…
Lord O’Shaughnessy, parliamentary under secretary of state for health in the UK, discusses how stakeholders are interacting to ensure that the UK remains at the forefront of the global life…
Ben Ellis, general manager at Lupin UK and Ireland, talks about the strategic challenges of transitioning from the sphere of generics to specialist pharma and how he hopes Lupin can…
Sir John Chisholm, executive chair of Genomics England – a company set up and owned by the UK Department of Health to run the 100,000 Genomes Project, which aims to…
Aisling Burnand, CEO of the Association of Medical Research Charities (AMRC), shares the organization’s vision and the significant contributions of its member charities to the life sciences R&D ecosystem in…
Michelle Mitchell, CEO of the Multiple Sclerosis Society in the UK since 2013, discusses her charity’s aims; their focus on research and development; funding in the face of Brexit; and…
See our Cookie Privacy Policy Here
